Company: SMNR
Filing Date: 2025-04-21
Form Type: CORRESP
Source: 0001193125-25-087365
Chunk: 17

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: CORRESP
Chunk 17
---
 these officers split their time between Semnur and Scilex and provide us with your legal analysis for not allocating any of the compensation 
 they received from Scilex to the executive compensation disclosure required by Item 402 for Semnur. Refer to Section 217.08 of the Regulation S-K Compliance and Disclosure Interpretations, available on                                             
 our website. Please provide a similar analysis for Stephen Ma as we note that you anticipate Stephen Ma will serve as New Semnur’s Chief Financial Officer following the closing of the Business Combination. Refer to Item 18(a)(7)(ii) of Form S-4. |

Response: The Company respectfully advises the Staff that it has revised the disclosure on page 358 of Amendment No. 1 in response to the Staff’s comment. 15

U.S. Securities and Exchange Commission April 21, 2025 Directors and Executive Officers of New Semnur after the Business Combination Executive Officers and Directors after the Business Combination, page 339

| 38. | We note that you anticipate the executive officers of New Semnur will be Jaisim Shah, Henry Ji, Ph.D.,                                                                      
 and Stephen Ma. Please clarify whether these officers will also retain their employment with Scilex and, if so, how they will allocate their time between the two entities. |

Response: The Company respectfully advises the Staff that it has revised the disclosure on pages 359, 366 and 367 of Amendment No. 1 in response to the Staff’s comment.

| 39. | Please provide the disclosures required by Item 401(f)(1) of Regulation                                                                                                                                                                                 
 S-K. Refer to Item 18(a)(7)(i) of Form S-4. In this regard, we note the involvement of Jaisim Shah and Dr. Henry Ji with Sorrento Therapeutics, Inc., which                                                                                             
 commenced voluntary bankruptcy proceedings in 2023. In addition, to the extent such proceedings, or proceedings arising therefrom, could have a material impact on you, the Business Combination, or New Semnur, please include appropriate risk factor 
 disclosure regarding the same.                                                                                                                                                                                                                          |

Response: The Company respectfully advises the Staff that it has revised the disclosure on page 369 of Amendment No. 1 in response to the Staff’s comment. The Company did not include risk factor disclosure related to the voluntary bankruptcy proceedings as the Company believes that such proceedings will not have a material impact on the Company, the Business Combination or New Semnur. Semn